Welcome to our dedicated page for Nexgel news (Ticker: NXGL), a resource for investors and traders seeking the latest updates and insights on Nexgel stock.
NexGel, Inc. develops and commercializes healthcare, beauty and over-the-counter products built around high-water-content hydrogel technology for healthcare and consumer applications.
Company news commonly covers operating and financial results, hydrogel and biomaterial product activity, strategic partnerships, acquisition and licensing activity, financing arrangements, and governance changes. Recent updates also document the launch of BioNX Surgical following a completed license and asset acquisition of commercial-stage regenerative biomaterial products.
NEXGEL (NASDAQ:NXGL) reported positive data from a randomized, 30-patient, single-center IRB study of its hydrogel laser treatment patch used in laser hair removal.
The patch achieved a 95.6% reduction in laser plume concentration versus control, lower mean pain scores (3.5 vs. 5.1), and numerically greater hair reduction (37.2% vs. 26.7%) at 90 days, with no adverse events. Results were published in Lasers in Surgery and Medicine in 2026.
NEXGEL (NASDAQ:NXGL) appointed Dave Hazard as Vice President of Sales for its BIONX Surgical division, effective May 13, 2026. The role supports commercialization of the newly launched division formed through a transformative acquisition expected to scale revenue.
Hazard brings extensive orthopedic, spine, and biologics sales leadership experience and prior partnerships relevant to BIONX Surgical.
NEXGEL (NASDAQ:NXGL) will report first quarter 2026 financial results for the period ended March 31, 2026 on Friday, May 15, 2026.
Management will host a conference call at 12:00 P.M. ET, with phone and webcast access plus replay options.
NEXGEL (NASDAQ: NXGL) appointed Brian J. Kieser, CPA and Kevin Harris, CFA from strategic partner Sequence LifeScience to its Board of Directors on May 6, 2026.
Sequence LifeScience led financing to close the acquisition of Celularity's degenerative disease segment with a $5.5 million strategic investment; management highlights partnership, industry experience, product innovation, and distribution support.
NEXGEL (NASDAQ:NXGL) named Ian Blackman, CPA, as Chief Financial Officer effective April 27, 2026. Mr. Blackman will support closing and integration of a definitive agreement to license and acquire commercial-stage regenerative biomaterial products from Celularity and scale NEXGEL’s consumer and healthcare businesses.
He brings over 30 years of finance and M&A experience, prior CFO roles in luxury consumer companies, and a record of revenue and EBITDA expansion in prior positions.
NEXGEL (NASDAQ: NXGL) closed the license and acquisition of Celularity's commercial-stage regenerative biomaterials portfolio and launched BioNX Surgical. The deal is led by a $5.5 million strategic investment from Sequence LifeScience™ and financed via a convertible note with a $0.60 conversion price and 50% warrant coverage. The transaction is expected to approximately triple pro-forma annual revenue to about $35 million and be immediately accretive to profitability, adding 6 established products with existing reimbursement and accelerating commercialization.
NEXGEL (NASDAQ:NXGL) moved its shareholder update conference call to April 21, 2026 at 4:30 P.M. ET to discuss the Celularity transaction. Investors can join via U.S. toll-free 1-800-267-6316, international 1-203-518-9783, or the company webcast under Events and Presentations.
NEXGEL (NASDAQ:NXGL) rescheduled its shareholder update conference call to April 23, 2026 at 4:30 P.M. ET to provide an update on the proposed transaction with Celularity.
The company said it will not finance the transaction under its previously announced Securities Purchase Agreement and is negotiating a new financing with a different investor group; additional details are expected on April 23.
Call details include U.S. toll-free 1-800-267-6316, international 1-203-518-9783, and a webcast via Events and Presentations.
NEXGEL (NASDAQ:NXGL) rescheduled its shareholder update conference call to April 15, 2026 at 4:30 P.M. ET to provide an update on the proposed Celularity transaction. The company said there is no assurance the transaction will close and it will not use the previously announced Securities Purchase Agreement financing.
The company is negotiating a new financing structure with a different group of investors and expects to provide additional transaction details on the April 15 call. Call and webcast access information has been provided for shareholders.
NEXGEL (NASDAQ:NXGL) rescheduled its fourth quarter and full-year 2025 financial results conference call to April 8, 2026 at 4:30 P.M. ET to allow more time to provide shareholders detail on its previously announced proposed transaction with Celularity.
The company filed its Form 10-K for year ended December 31, 2025 with the SEC on March 31, 2026. Call dial-in numbers and a webcast will be available for investors.